Serum chemokine levels differentially regulated by vorinostat in a Sézary syndrome patient.
Serum chemokine levels differentially regulated by vorinostat in a Sézary syndrome patient.
复制标题
伏立诺他对塞扎里综合征患者血清趋化因子水平的差异调节。
DOI:
10.1111/bjd.13696
复制
发表时间:
2015
期刊:
影响因子:
--
通讯作者:
Sato S
中科院分区:
文献类型:
--
作者:
Miyagaki T;Sugaya M;Oka T;Fujita H;Sato S
3 Sviggum HP, Davis MD, Rajkumar SV, Dispenzieri A. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol 2006; 142: 1298–302. 4 Michot C, Guillot B, Dereure O. Lenalidomide-induced acute acneiform folliculitis of the head and neck: not only the anti-EGF receptor agents. Dermatology 2010; 220: 49–50. 5 Gilaberte Y, Coscojuela C, Vazquez C et al. Perforating folliculitis associated with tumour necrosis factor-alpha inhibitors administered for rheumatoid arthritis. Br J Dermatol 2007; 156: 368–71. 6 Noman AS, Koide N, Khuda II et al. Thalidomide inhibits epidermal growth factor-induced cell growth in mouse and human monocytic leukemia cells via Ras inactivation. Biochem Biophys Res Commun 2008; 374: 683–7.